{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T04:34:58Z","timestamp":1726806898457},"reference-count":9,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.annder.2024.103310","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T03:46:31Z","timestamp":1724730391000},"page":"103310","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe cholinergic urticaria: Clinical characteristics and therapeutic approach"],"prefix":"10.1016","volume":"151","author":[{"given":"J.","family":"Castagna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Tetart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Badaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Amsler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Pralong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Castelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2024.103310_b0005","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/all.12884","article-title":"The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI\/GA(2) LEN\/EDF\/UNEV consensus recommendations 2016 update and revision","volume":"71","author":"Magerl","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2024.103310_b0010","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaci.2018.08.050","article-title":"Real-life treatment of cholinergic urticaria with omalizumab","volume":"143","author":"Altrichter","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2024.103310_b0015","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jaip.2018.12.025","article-title":"Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial","volume":"7","author":"Gastaminza","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2024.103310_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.05.026","article-title":"Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria","volume":"138","author":"Koch","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.annder.2024.103310_b0025","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1111\/ajd.12496","article-title":"Cholinergic urticaria: More than a simple inducible urticaria","volume":"58","author":"Kim","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annder.2024.103310_b0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40257-022-00728-6","article-title":"Cholinergic Urticaria: Subtype Classification and Clinical Approach","volume":"24","author":"Fukunaga","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.annder.2024.103310_b0035","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jaip.2015.09.021","article-title":"Cholinergic Urticaria with Anaphylaxis: An Underrecognized Clinical Entity","volume":"4","author":"Vadas","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2024.103310_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2018.10.013","article-title":"Angioedema frequently occurs in cholinergic urticaria","volume":"7","author":"Mellerowicz","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.annder.2024.103310_b0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CCID.S343462","article-title":"Cholinergic urticaria, an effective and safe \u201coff label\u201d use of dupilumab: a case report with literature review","volume":"15","author":"Sirufo","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T22:49:51Z","timestamp":1726786191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963824000668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0151963824000668"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2024.103310","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe cholinergic urticaria: Clinical characteristics and therapeutic approach","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2024.103310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103310"}}